Predict your next investment

Ralexar Therapeutics company logo
HEALTHCARE | Drug Development
ralexar.com

See what CB Insights has to offer

Founded Year

2014

Stage

Series C | Alive

Total Raised

$29.93M

Last Raised

$4.28M | 3 yrs ago

About Ralexar Therapeutics

Ralexar Therapeutics is a privately held specialty pharmaceutical company developing topical and systemic therapies based on Liver X Receptor (LXR) modulators. The initial focus for the company is on the clinical development of ALX-101, a topical LXR-based therapy, for the treatment of various cutaneous inflammatory disorders, including atopic dermatitis.

Ralexar Therapeutics Headquarter Location

640 Lee Road Suite 118

Wayne, Pennsylvania, 19087,

United States

484-318-2988

Latest Ralexar Therapeutics News

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ralexar Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ralexar Therapeutics is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Ralexar Therapeutics Patents

Ralexar Therapeutics has filed 8 patents.

The 3 most popular patent topics include:

  • Intracellular receptors
  • Transcription factors
  • Antiandrogens
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/6/2019

6/15/2021

Transcription factors, Intracellular receptors, Trifluoromethyl compounds, Prodrugs, G protein coupled receptors

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/6/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/15/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Transcription factors, Intracellular receptors, Trifluoromethyl compounds, Prodrugs, G protein coupled receptors

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.